Search Legislation

The Human Medicines (Amendments Relating to the Early Access to Medicines Scheme) Regulations 2022

 Help about what version

What Version

  • Latest available (Revised)
  • Original (As made)
 Help about opening options

Opening OptionsExpand opening options

Status:

This is the original version (as it was originally made). This item of legislation is currently only available in its original format.

Amendment of regulation 2

This section has no associated Explanatory Memorandum

16.  Regulation 2(1)(1) (interpretation), at the appropriate places in the alphabetical order insert—

EAMS medicinal product” means a medicinal product that—

(a)

has been included in the Early Access to Medicines Scheme by means of the licensing authority issuing an EAMS scientific opinion in respect of it; and

(b)

remains in the scheme by virtue of the EAMS scientific opinion not ceasing to have effect in respect of it by virtue of regulation 167D of the 2012 Regulations;;

EAMS scientific opinion” is to be construed in accordance with regulation 167C(2)(b) of the 2012 Regulations;; and

Early Access to Medicines Scheme” means the scheme of that name established and operated under regulation 167C(1) of the 2012 Regulations;.

Back to top

Options/Help